Richards A Mark
National Heart Foundation of New Zealand, New Zealand.
Heart Fail Clin. 2009 Oct;5(4):463-70. doi: 10.1016/j.hfc.2009.04.011.
A profusion of circulating candidate biomarkers in heart failure is currently being investigated. Although all will advance our insight into the pathophysiology of heart failure, their potential clinical utility will depend on satisfaction of three key criteria. Assays must be accessible, reliable, and affordable. Secondly, the marker must provide information about cardiac function and prognosis not otherwise available. Finally, measurement of the marker must demonstrably lead to improved management and better clinical outcomes. Despite many promising candidates requiring fuller investigation, currently, only the natriuretic peptides satisfy these requirements.
目前正在研究心力衰竭中大量循环的候选生物标志物。尽管所有这些标志物都将增进我们对心力衰竭病理生理学的了解，但其潜在的临床效用将取决于是否满足三个关键标准。检测方法必须易于获得、可靠且价格合理。其次，该标志物必须提供有关心脏功能和预后的其他途径无法获得的信息。最后，该标志物的测量必须能明显改善治疗管理并带来更好的临床结果。尽管有许多有前景的候选标志物需要更充分的研究，但目前只有利钠肽满足这些要求。
